Alpha Teknova/$TKNO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Alpha Teknova
Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.
Ticker
$TKNO
Sector
Primary listing
Employees
173
Headquarters
Website
Alpha Teknova Metrics
BasicAdvanced
$304M
-
-$0.41
0.32
-
Price and volume
Market cap
$304M
Beta
0.32
52-week high
$7.48
52-week low
$3.94
Average daily volume
318K
Financial strength
Current ratio
5.875
Quick ratio
4.498
Long term debt to equity
35.61
Total debt to equity
38.09
Interest coverage (TTM)
-36.80%
Profitability
EBITDA (TTM)
-13.524
Gross margin (TTM)
23.66%
Net profit margin (TTM)
-55.23%
Operating margin (TTM)
-54.75%
Effective tax rate (TTM)
0.02%
Revenue per employee (TTM)
$220,000
Management effectiveness
Return on assets (TTM)
-11.79%
Return on equity (TTM)
-27.74%
Valuation
Price to revenue (TTM)
7.741
Price to book
3.99
Price to tangible book (TTM)
4.78
Price to free cash flow (TTM)
-28.67
Free cash flow yield (TTM)
-3.49%
Free cash flow per share (TTM)
-0.198
Growth
Revenue change (TTM)
11.40%
Earnings per share change (TTM)
-54.92%
3-year revenue growth (CAGR)
-2.77%
3-year earnings per share growth (CAGR)
-15.06%
Bulls say / Bears say
Alpha Teknova achieved 7% year-over-year revenue growth to reach $10.3 million in Q2 2025, marking its fourth straight quarter of rising sales. (Nasdaq)
The company’s gross margin increased to 38.7% in Q2 2025 from 29.2% a year earlier, driven by manufacturing improvements and a better product mix. (Nasdaq)
In Q1 2025, Teknova entered an exclusive partnership with Pluristyx, Inc. to manufacture and distribute the new PluriFreeze™ cryopreservation system, expanding its cell therapy reagents portfolio. (GlobeNewswire)
Despite revenue growth, Teknova reported a net loss of $3.6 million in Q2 2025, highlighting ongoing unprofitability. (Nasdaq)
Free cash flow remained negative at $2.3 million in Q2 2025, indicating continued cash burn and liquidity pressures. (Nasdaq)
Teknova filed for a $225 million mixed securities shelf offering in July 2025, which could significantly dilute existing shareholders. (GuruFocus)
Data summarised monthly by Lightyear AI. Last updated on 27 Sept 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Alpha Teknova stock?
Alpha Teknova (TKNO) has a market cap of $304M as of October 26, 2025.
What is the P/E ratio for Alpha Teknova stock?
The price to earnings (P/E) ratio for Alpha Teknova (TKNO) stock is 0 as of October 26, 2025.
Does Alpha Teknova stock pay dividends?
No, Alpha Teknova (TKNO) stock does not pay dividends to its shareholders as of October 26, 2025.
When is the next Alpha Teknova dividend payment date?
Alpha Teknova (TKNO) stock does not pay dividends to its shareholders.
What is the beta indicator for Alpha Teknova?
Alpha Teknova (TKNO) has a beta rating of 0.32. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.